EP0647649A1 — Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
Assigned to Yamanouchi Pharmaceutical Co Ltd · Expires 1995-04-12 · 31y expired
What this patent protects
Crystal D or E of 1-hydroxy-2-(imidazo[1,2-a]-pyridin-3-yl)ethane-1,1-bis(phosphonic acid) monohydrate having specified lattice spacing and relative intensity in the powder X-ray diffraction spectrum obtained by using Cu-K alpha radiation and a dehydration peak temperature of 13…
USPTO Abstract
Crystal D or E of 1-hydroxy-2-(imidazo[1,2-a]-pyridin-3-yl)ethane-1,1-bis(phosphonic acid) monohydrate having specified lattice spacing and relative intensity in the powder X-ray diffraction spectrum obtained by using Cu-K alpha radiation and a dehydration peak temperature of 135-149 DEG C or 160-170 DEG C according to TG-DSC thermogravimetric analysis; and a solid pharmaceutical preparation containing the same. The crystals are useful for producing a stable solid preparation of the above compound which has an excellent drug efficacy for diseases wherein increased bone resorption participates, such as osteoporosis.
Drugs covered by this patent
- Sustiva (EFAVIRENZ) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.